Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 5Active not recruiting 5Not yet recruiting 4Withdrawn 1Terminated 1Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Locally Recurrent Skin Squamous Cell Carcinoma 1

Interventions

Specimen Handling 33Magnetic Resonance Spectroscopy 21Biopsy 19Cyclophosphamide 10venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Vincristine 5Etoposide 5Bevacizumab 5fludarabine phosphate 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Radiosurgery 4Radiation 4Injections 4Doxorubicin 4Cisplatin 4fludarabine 3durvalumab 3decitabine and cedazuridine drug combination 3X-Rays 3Taxes 3Tacrolimus 3Surveys and Questionnaires 3Prednisone 3Leucovorin 3Irinotecan 3Ipilimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Hyaluronoglucosaminidase × 1 year × Clear all
NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡